Other

Revised: November 6, 2026

Note: Click on a trial title for more information.

Key:

  • Open
  • Other Hematologic Disorders

    Other

    • VICC-ITHEM23019

      Phase II Study of Inflamm Modif of Canakinumab to Prevent Leukemic Progression of CCUS

    • VICCCTT1875

      A Phase 3 Study of Tabelecleucel for Subjects with Epstein-Barr Virus-Associated Post-Transplant Lym

      • Off the shelf allogeneic EBV specific T cells for PTLD

        Key Eligibility:

        Prior allo-HCT required
        Progressive disease after 3 doses of Rituxan +- chemo or stable disease after 4 doses of Rituxan
        CNS disease must be controlled

        Schedule:

        Outpatient IV injection day 1, 8, 15 of 35 day cycle. Up to 4 cycles allowed.